Background {#Sec1}
==========

Quinolones are groups of antibacterial drugs having an extensive application in both clinical and veterinary medicine. The older (first generation) quinolones including nalidixic acid and cinoxacin were primarily used for the treatment of urinary tract infections as their concentration in urine is relatively higher than that of the plasma. In 1980s, the introduction of fluorinated derivatives (fluoroquinolones) such as ciprofloxacin and norfloxacin became a major breakthrough in the development of relatively safer, orally effective and entirely synthetic broad spectrum antibacterial agents \[[@CR1], [@CR2]\]. As a result, quinolones have been routinely used for several bacterial infections. Recently, ciprofloxacin was pointed out as the most consumed antibacterial agent world-wide. Within a second generation quinolones, it has a sound medical importance in treating infections caused by many enterobacteriaceae and other gram-negative bacilli. Ciprofloxacin is the most potent of fluoroquinolones for pseudomonal infections associated with cystic fibrosis. However, their widespread use with some degree of evidence of misuse or use of these agents to micro-organisms to which they have poor activity has been blamed for the rapid development of resistance to these agents \[[@CR3], [@CR4]\].

In Ethiopia, ciprofloxacin has become the most commonly utilized fluoroquinolone and one of the top three antibacterial agents in clinical practice \[[@CR5]--[@CR8]\]. Study conducted by Birru et al. indicated that there is a high degree of inappropriate use of ciprofloxacin. The study emphasized that nearly half of the treatment was shown to have inappropriate dosage regimen with the duration of therapy being the dominant one in Boru Meda Hospital \[[@CR9]\]. Such inappropriate use paves a way forward for the emergence and spread of antimicrobial resistance (AMR). AMR can result from mutations in housekeeping structural or regulatory genes as well as from horizontal acquisition of foreign genetic information \[[@CR10]--[@CR12]\]. Resistance to the quinolones often emerges at low-levels by acquisition of an initial resistance conferring mutation. Acquisition of subsequent mutations leads to higher levels of resistance against second and newer-generation quinolones such as ciprofloxacin \[[@CR13]\]. At present, AMR is resulting in increased morbidity, mortality, and healthcare costs in developing countries \[[@CR14]\]. This study is, therefore, aimed to quantitatively estimate ciprofloxacin resistance among clinically relevant bacterial isolates in Ethiopia.

Methods {#Sec2}
=======

Study protocol {#Sec3}
--------------

The identification of records, screening of titles and abstracts as well as evaluation of eligibility of full texts for final inclusion was conducted in accordance with the Preferred Reporting Items for Systematic review and Meta-analysis (PRISMA) flow diagram \[[@CR15]\]. PRISMA checklist \[[@CR16]\] was also strictly followed while conducting this systematic review and meta-analysis. The completed checklist has been provided as supplementary material (Additional file [1](#MOESM1){ref-type="media"}: Table S1). The study protocol is registered on PROSPERO with reference number ID: CRD42018097047 and the published methodology is available online from: <http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018097047>

Identification of records and search strategy {#Sec4}
---------------------------------------------

Literature search was carried out through visiting legitimate databases and indexing services-PubMed/MEDLINE, EMBASE (Ovid interface) and other supplementary sources including Google Scholar, WorldCat catalog, ResearchGate and Cochrane library. Advanced search strategies were applied in major databases to retrieve relevant findings closely related to resistance/susceptibility of isolates to ciprofloxacin. Articles published in subscription based journals under Science-Direct and Wiley online library were accessed through HINARI:WHO for developing countries. The search was conducted with the aid of carefully selected key-words and indexing terms within specified time (online records from 2015- May, 2018). Excluding the non-explanatory terms, the search strategy included "quinolone \[MeSH\]", ciprofloxacin \[MeSH\], "antimicrobial susceptibility", "antimicrobial resistance", "antibacterial sensitivity" and "Ethiopia". Boolean operators (AND, OR), truncation and MeSH terms were used appropriately for systematic identification of records for the research question. The search was conducted from 25 April to 10 May, 2018 and all published and unpublished articles available online till the day of data collection were considered. Gray literatures from organizations and online university repositories were accessed through Google Scholar and WorldCat.

Screening and eligibility of studies {#Sec5}
------------------------------------

Records identified from various electronic databases, indexing services and directories were exported to ENDNOTE reference software version 8.2 (Thomson Reuters, Stamford, CT, USA) with compatible formats. Duplicate records were identified, recorded and removed with ENDNOTE. Some duplicates were addressed manually due to variation in reference styles across sources. Thereafter, two authors (MS and FW) independently screened the title and abstracts with predefined inclusion criteria. Two authors (MS and TT) also independently collected full texts and evaluated the eligibility of them for final inclusion. In each case, the rest authors played a critical role in solving discrepancies arose between two authors to come into consensus.

Inclusion and exclusion criteria {#Sec6}
--------------------------------

During initial screening of titles and abstracts as well as evaluating full texts for eligibility, there have been predefined inclusion-exclusion criteria. Cross sectional studies addressing the prevalence of ciprofloxacin-resistant bacterial isolates obtained from human source (patients) regardless of the clinical characteristics and nature of specimen were included. Only English language literatures and online records published from 2015 to May, 2018 were considered for further eligibility assessment. All review articles and original articles conducted outside of Ethiopia were excluded during initial screening. Articles with irretrievable full texts (after requesting full texts from the corresponding authors via email and/or ResearchGate), records with unrelated outcome measures, articles with missing or insufficient outcomes were excluded.

Data extraction {#Sec7}
---------------

With the help of standardized data abstraction format prepared in Microsoft Excel (Additional file [2](#MOESM2){ref-type="media"}: Table S2), two authors (MS and HM) independently extracted important data related to study characteristics (study area, first author, year of publication, study design, patient characteristics, source of isolates, types of isolates, and number of isolates) and outcome of interest (number of resistant isolates for each bacterium).

Critical appraisal of studies {#Sec8}
-----------------------------

The quality of studies was evaluated according to Newcastle-Ottawa scale adapted for cross-sectional studies \[[@CR17]\] and graded out of 10 points (stars). For ease of assessment, the tool has included important indicators categorized in to three major sections: 1) the first secstion assesses the methodological quality of each study and weighs a maximum of five stars 2) the second section considers comparability of the study and takes 2 stars 3) the remaining section assess outcomes with related to statistical analysis. This critical appraisal was conducted to assess the internal (systematic error) and external validity of studies and to reduce the risk of biases in individual studies. The mean score of two authors were taken for final decision and studies with score greater than or equal to five were included.

Outcome measurements {#Sec9}
--------------------

The primary outcome measure is the prevalence of ciprofloxacin resistant bacterial isolates in Ethiopia. It is aimed to assess the pooled estimates of antibacterial resistance at the national level. The measurement was conducted for selected gram-positive (*Staphylococcous aureus*; Coagulase negative staphylococci (CoNS), Group B Streptococci (GBS) and *Enterococcus faecalis)* and gram-negative bacterial isolates (*Escherichia coli*, *Klebsiella pneumonia*, *Pseudomonas aueroginosa*, Proteus species, *Neisseria gonorrhea*, and other enteric microorganisms) obtained from patients with presumed or confirmed infectious diseases. Subgroup analysis was also conducted based on the source of bacterial isolates.

Data processing and statistical analysis {#Sec10}
----------------------------------------

The relevant data were extracted from included studies using format prepared in Microsoft Excel and exported to STATA 15.0 for outcome measures and subgroup analyses. Considering variation in true effect sizes across population (clinical heterogeneity), Der Simonian and Laird's random effects model was applied for the analyses at 95% confidence level. Heterogeneity of studies was determined using I^2^ statistics. Comprehensive Meta-analysis version-3 software (Biostat, Englewood, New Jersey, USA) was used for publication bias assessment. For gram-positive and gram-negative bacterial isolates, the presence of publication bias was evaluated by using the Begg's and Egger's tests and presented with funnel plots of standard error of Logit event rate \[[@CR18], [@CR19]\]. A statistical test with a *p*-value less than 0.05 (one tailed) was considered significant.

Results {#Sec11}
=======

Search results {#Sec12}
--------------

A total of 416 records were identified from several sources including PubMed/MEDLINE, EMBASE, Google Scholar, Science Direct and WorldCat catalog. From these, 137 duplicate articles were removed with the help of ENDNOTE and manual tracing. The remaining 279 records were screened using their titles and abstracts and 225 of them were excluded. Full texts of 54 records were then evaluated for eligibility. From these, 17 articles were also excluded as the outcome of interest was found missing, insufficient and/or ambiguous. Finally, 37 articles have passed the eligibility criteria and quality assessment and hence included in the study (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1PRISMA flow chart describing the selection process

Study characteristics {#Sec13}
---------------------

As shown in Table [1](#Tab1){ref-type="table"}, a total of 37 studies with 3235 selected bacterial isolates (1303 gram-positive and 1932 gram-negative) were included for systematic review and meta-analysis. We included studies that employed both retrospective and prospective cross-sectional study design. The year of publication of included studies ranged from 2015 to 10 May 2018 since antimicrobial resistance is highly time-sensitive. The study included a wide range of clinical characteristics of patients, sources of isolates (specimens), nature of bacterial isolates and effect sizes. Patients with presumed or confirmed urinary tract infections took larger proportion of participants and midstream urine sample was the major source of bacterial isolates \[[@CR20]--[@CR29]\]. The rest sources of isolates were blood from septicemia and febrile patients \[[@CR30]--[@CR34]\], stool from patients with acute diarrhea \[[@CR35]--[@CR39]\], external ocular discharges from patients with ocular infections \[[@CR40]--[@CR42]\], vaginal discharges from pregnant women with infections \[[@CR43]--[@CR45]\], ear discharges with bacterial otitis media \[[@CR46]--[@CR48]\], and wound swabs from infected wounds \[[@CR49], [@CR50]\], among others. Some samples were taken from more than one source in a given patient \[[@CR51]--[@CR55]\]. Six of the included studies were retrospective analyses of secondary data \[[@CR23], [@CR28], [@CR46], [@CR47], [@CR49], [@CR52]\]. Majority of the isolates from stool were enteric gram-negative micro-organisms (salmonella and shigella) and gram positive enterococci. The average quality scores of studies ranged from 6 to 10 as per the Newcastle-Ottawa scale (Table [1](#Tab1){ref-type="table"}).Table 1Characteristics of studies describing the resistance profile of clinical relevant bacterial isolates against ciprofloxacinStudy IDQuality scoreYear (pub)Study AreaStudy DesignPopulation (Clinical features)Source of sampleBacterial CategoryType of isolatesNumber of isolatesNo of resistant(%)Abamecha et al. \[[@CR35]\]8.52015JUSHCSHospitalized patientsStoolGram + Ve*E. faecalis*1145750.00Abera et al. \[[@CR51]\]92016FHRHCSIn/outpatients with infectionsUrine and BloodGram -Ve*E. coli*1224940.16*K. Pneumoniae*492857.14*P. mirabilis*291034.48Alemseged et al. \[[@CR43]\]82015ARH and MHC, MekeleCSPregnant womenVaginal swabsGram + VeGBS1915.26Ali et al. \[[@CR78]\]8.52016Gambella hospitalCSSTI suspected patientsUrethral or endo-cervical swabsGram -Ve*N. gonorrhoeae*21628.57Ameya et al. \[[@CR36]\]82018Arba Minch provinceCSUnder five children (diarrhea)StoolGram -VeSalmonela2100.00Shigella800.00Denboba et al. \[[@CR46]\]7.52016DRHRLCS (R)Patients with Otitis mediaEar dischargesGram + Ve*S. auerus*10210.98Gram -VePseudomonas spp134139.70Proteus spp11487.02*K. pneumoniae*900.00*E. coli*6968.70Assefa et al. \[[@CR55]\]82015UoGHCSDacryocystitis patientsNasolacrim al dischargeGram + Ve*S. auerus*600.00CoNS9444.44Ayelign et al. \[[@CR20]\]8.52018UoGHCSPediatric patients with UTIUrine specimensGram + Ve*S. auerus*800.00Gram -Ve*E. coli*45817.78Pseudomonas spp8112.50Bekele et al. \[[@CR21]\]72015JUSHCSCatheterized patientsUrine samples (Catheter)Gram -VePseudomonas spp3600.00Bitew et al. \[[@CR22]\]8.52017Arsho AML, AACSPatients with UTIUrineGram + Ve*S. auerus*9333.33*E. faecalis*1417.14Gram -Ve*E. coli*1356850.37*K. pneumoniae*18316.67Deribe et al. \[[@CR23]\]6.52017Bahir Dar Regional HRLCCS (R)Patient with presumptive UTIUrineGram + Ve*S. auerus*9333.33Gram -Ve*E. coli*644164.06*K. pneumoniae*19421.05Pseudomonas spp800.00Proteus spp6466.67Dereje et al. \[[@CR24]\]8.52017Hamlin fistula hospital, AACSFistula patients (UTI)UrineGram -Ve*E. coli*653756.92*K. pneumoniae*141178.57Proteus spp311445.16Derese et al. \[[@CR25]\]9.52016DRHCSPregnant women with UTIUrineGram + VeCoNS5120.00Gram -Ve*E. coli*9111.11Dessie et al. \[[@CR50]\]92016Selected referral hospitals, AACSSurgical site infected patientsWound swabsGram + Ve*S. auerus*19315.79Gram -Ve*E. coli*241666.67*K. pneumoniae*10220.00Pseudomonas spp6233.33Eshetie et al. \[[@CR26]\]9.52015UoGHCSPatients with UTIUrineGram -Ve*E. coli*10410.96*K. pneumoniae*28310.71Gebrekidan et al. \[[@CR37]\]7.52015Mekele hospitalCSOutpatients with acute diarrheaStoolGram -VeShigella1516.67Teweldemedihin \[[@CR40]\]82017Quiha Ophthalmic HospitalCSPatients with ocular infectionsOcular specimensGram + Ve*S. auerus*40512.50CoNS3139.68*E. faecalis*8112.50*K. Pneumonia*7114.29Pseudomonas spp21419.05*E. coli*1516.67Getahun et al. \[[@CR41]\]102017UoGHCSPatients with ocular infectionsOcular samples/ externalGram + Ve*S. auerus*9677.29CoNS64710.94Gram -2015Ve*E. coli*6116.67*K. pneumoniae*9222.22Gezmu et al. \[[@CR27]\]62016Arba Minch HospitalCSPatients with UTIUrineGram + Ve*S. auerus*10330.00Gram -Ve*E. coli*20420.00*K. pneumoniae*8225.00Hailu et al. \[[@CR34]\]82016Bahir Dar Reg HRLCCSFebrile patientsBloodGram + Ve*S. auerus*501020.00CoNS3538.57Gram -Ve*E. coli*19526.32*K. pneumoniae*351028.57Pseudomonas spp15213.33Hailu et al. \[[@CR49]\]7.52016Bahir Dar Regional HRLCCS (R)Patiets with infected woundswound swabGram + Ve*S. auerus*6757.46*S. pyogens*2015.00Gram -Ve*E. coli*331545.45*K. Pneumonia*20420.00Pseudomonas spp26519.23Proteus spp22522.73Hailu et al. \[[@CR47]\]7.52016Bahir Dar Regional HRLCCS (R)Patients with ear infectionsEar dischargesGram + Ve*S. auerus*7800.00CoNS3400.00*S .pneumonia*700.00Gram -Ve*E. coli*7114.29*K. Pneumoniae*10110.00Pseudomonas spp8877.95Proteus spp6534.62Kumalo et al. \[[@CR30]\]72016JUSHCSSepsis patientsBloodGram + Ve*S. auerus*6116.67Lamboro et al. \[[@CR38]\]8.52016JUSHCSOutpatients with diarrheaStoolGram -VeSalmonella1900.00Mengist et al. \[[@CR44]\]72016JUSHCSPregnant womenAnorectal and VaginalGram + VeGBS3139.68Mitku \[[@CR28]\]6.52017DRHRLCS (R)Outpatients with UTIUrineGram -Ve*E. coli*2528.00*K. Pneumoniae*7114.29Proteus spp6116.67Mulu et al. \[[@CR52]\]8.52017DMRHCS (R)Any patients with infectionNon specific/ all typesGram + Ve*S. auerus*13646.15Gram -Ve*E. coli*22418.18Pseudomonas spp17635.29Salmonella16425.00*N. gonorrheae*81361.53Negussie et al. \[[@CR31]\]6.52015Selected hospitals, AACSSepticemia suspected childrenBloodGram + Ve*S. auerus*13430.77CoNS11218.18Gram -Ve*K. pneumoniae*9444.44Nigussie and Amsalu \[[@CR29]\]7.5201HURHCSDiabetic patientsUrineGram + Ve*S. auerus*6350.00CoNS8450.00Gram -Ve*E. coli*11218.18Regassa et al. \[[@CR53]\]82015JUSHCSCAP paientsSputum and BloodGram + Ve*S. auerus*16531.25Gram -VePseudomonas spp10220.00*K. pneumoniae*800.00Sahile et al. \[[@CR54]\]62016JUSHCSPatients with surgical and gynecologic woundUrine and wound swabGram + Ve*S. auerus*221359.09CoNS211676.19Gram -Ve*E. coli*9444.44Pseudomonas spp8450.00Proteus spp7342.86Shiferaw et al. \[[@CR42]\]8.52015BoruMeda HospitalCSPatients with ex-ocular infectionsExternal ocular specimensGram + Ve*S. auerus*2129.52CoNS5147.84*S. pneumoniae*10220.00*S. pyogens*600.00Terfasa and Jida \[[@CR39]\]82018Nekemte referral hospitalCSDiarrheal patientsStoolGram -VeSalmonella3026.67Shigella900.00Wasihun et al. \[[@CR32]\]82015Mekelle hospitalCSFebrile patientsBloodGram + Ve*S. auerus*542138.89CoNS441125.00Gram -Ve*E. coli*1616.25Salmonela8450.00Wasihun et al. \[[@CR33]\]8.52015Mekelle hospialCSFebrile patientsBloodGram + Ve*S. auerus*411843.90CoNS391025.64*S. pyogens*6116.67Gram -Ve*E. coli*1218.33Salmonella8112.50Wasihun and Zemene \[[@CR48]\]82015ARHCSPatients with otitis mediaEar dischargesGram + Ve*S. auerus*461021.74CoNS17952.94*S. pneumonia*15320.00*S. pyogens*16318.75Gram -VeProteus spp3900.00Pseudomonas spp271037.04*K. pneumoniae*18211.11*E. coli*6116.67Mulu et al. \[[@CR45]\]72015FHRHCSWomen with vaginal infectionsVaginal swabsGram + Ve*S. auerus*15320.00Gram -Ve*E. coli*6233.33Pseudomonas spp700.00*Abbreviations*: *CoNS* coagulase negative Staphylococci, *CS* cross-sectional, *R* retrospective, *HURH* Hawassa University Referral Hospital, *UoGH* University of Gondar Hospital; *JUSH* Jimma University Specialized Hospital, *DRHRL* Dessie Regional Health Research laboratory, *STI* sexually transmitted diseases, *UTI* Urinary tract infections, *ARH* Ayder Referral Hospital, *GBS* Group B Streptococci, *FHRH* Felege Hiwot Referral Hospital, *DMRH* Debre Markos Referral Hospital, *CAP Community Acquired Pneumonia*

Study outcome measures {#Sec14}
----------------------

### Gram-positive bacteria {#Sec15}

The overall estimate of resistance in selected gram-positive bacterial isolates against ciprofloxacin was found to be 19% (95% CI: 15, 23) (Fig. [2](#Fig2){ref-type="fig"}). In this category, the pooled estimates of resistance in *S. auerus* was 18.6% (95% CI: 13.5, 23.7) with degree of heterogeneity (I^2^), 88.18%. The resistance level of CoNS isolates was found to be 21.6% (95% CI: 12.4, 30.8). Higher degree of resistance was observed among *Enterococcus faecalis* with prevalence rate of 23.9%. There was low level of ciprofloxacin resistance in GBS isolates (7.40%) (Table [2](#Tab2){ref-type="table"}).Fig. 2Pooled estimate of resistance in gram-positive bacteria against ciprofloxacin in EthiopiaTable 2Subgroup analyses of resistance profiles of gram-positive and gram-negative bacterial isolates against ciprofloxacinCategoryBacterial isolatesPooled estimate (95% CI)Gram positive bacteria*S. aureus*18.6% (13.5, 23.7)CoNS21.6% (12.4, 30.8)*E. faecalis*23.9% (7.9, 55.7)GBS7.4% (0.2, 14.6)Gram negative bacteria*E. coli*24.3% (14.2, 34.3)*K. pneumoniae*23.2% (13.7, 32.7)*N. gonorrhea*48.1% (18.3,87.9)Pseudomonas spp14.1% (8.3, 19.8)Proteus spp16.0% (7.9, 24.1)Other enteric pathogens\
(Shigella and salmonella)6.3% (1.50, 11.1)*GBS* Group B Streptococci, *CoNS* Coagulase Negative Staphylococci

### Gram-negative bacteria {#Sec16}

The gram-negative bacteria were the most common isolates obtained from several sources. The pooled estimate of resistance was 21% (95% CI: 17, 25) (Fig. [3](#Fig3){ref-type="fig"}). Among the selected isolates, higher degree of resistance was observed in *N. gonorrhea*, *E. coli* and *K. pneumoniae* with prevalence of 48.1, 24.3 and 23.2%, respectively. Besides, the pooled estimates of resistance in Proteus species (mainly *P. mirabilis*) and Pseudomonas species (primarily *P. aueroginosa*) against ciprofloxacin were found to be 16.0% (95% CI: 7.9, 24.1) and 14.1% (95% CI: 8.3, 19.8), respectively. The lowest degree of resistance was found among other gram negative enteric pathogens (salmonella and shigella) obtained from stool in patients with acute diarrhea. The overall estimate of resistance in these enteric species was found to be 6.3% (95% CI: 1.5, 11.1). Individual isolate (subgroup analysis) indicated that the prevalence of resistance in salmonella and shigella species was 8.1 and 5.8%, respectively (Table [2](#Tab2){ref-type="table"}). In addition, we performed a univariate meta-regression model to identify whether sample size of individual isolates is a possible sources of heterogeneity; however, only the sampling distribution of *S. aureus* was found to be statistically significant (*p* value = 0.005) (Table [3](#Tab3){ref-type="table"}).Fig. 3Forest plot depicting the resistance profile of gram-negative bacteria against ciprofloxacinTable 3Univariate meta-regression model describing whether sample size is considered as a possible source of heterogeneityNature of bacterial isolatesRegression coefficients (95% CI)*p* value*S. aureus*−0.003 (−0.005, −0.001)0.005^\*^CoNS−0.003 (−0.007, 0.002)0.238*E. coli*0.001 (−0.001, 0.003)0.200Pseudomonas spp0.000 (−0.001, 0.001)0.577*K. pneumoniae*0.007 (0.000, 0.014)0.059Proteus spp−0.003 (− 0.006, 0.000)0.077Other pathogens−0.002 (− 0.008, 0.003)0.450^\*^ Statistically significant at *p* value \< 0.05

### Source based subgroup and sensitivity analyses {#Sec17}

There was a significant change on the degree of heterogeneity when we had excluded the expected outliers and studies with few numbers of isolates (less than five) per bacterium from the analyses. Very few sample size significantly affected the confidence intervals and point estimates. Therefore, we were subjected to exclude some of the studies for the meta-analysis at the initial scenario. We also conducted a subgroup analysis based on the source of bacterial isolates. These analyses further clarify whether there is a clinically significant difference in the degree of resistance of bacterial isolates across sources of specimens. Highest prevalence of resistant isolates was obtained from urine sample for CoNS (36%), *K. pneumoniae* (32%) and Proteus species (40%). Among the common sources, blood sample was endowed with larger proportion of resistant isolates of *S. aureus* 33% (95% CI: 20, 45). The resistance rates of *E. coli* and *Pseudomonas spp* from wound swabs and vaginal discharges, respectively, was found to be high (Table [4](#Tab4){ref-type="table"}).Table 4Subgroup analysis of resistance profiles by the source of specimensCommon bacterial isolates, Proportion (95% CI)Common source*S. aureusCoNSE.coliPseudomonas sppKlebsiella sppProteus spp*Urine0.26 (0.03, 0.50)0.36 (0.12, 0.84)0.27 (0.10, 0.43)0.02 (0.00, 0.05)0.32 (0.12, 0.51)0.40 (0.27, 0.52)Blood0.33 (0.20, 0.45)0.19 (0.09, 0.28)0.11(0.01, 0.22)0.16 (0.02, 0.29)0.23 (0.03, 0.43)--Ear discharges0.03 (0.00,0.07)0.26 (0.14, 0.76)0.09 (0.03, 0.15)0.09 (0.05, 0.13)0.08 (0.00, 0.17)0.04 (0.00, 0.08)Wound swabs0.08 (0.01,0.14)--0.56 (0.35, 0.76)0.19 (0.04, 0.34)0.20 (0.05, 0.34)0.23 (0.05, 0.40)Ocular discharges0.09 (0.04, 0.13)0.08 (0.04, 0.12)0.08 (0.03, 0.20)0.19 (0.02, 0.35)0.18 (0.00, 0.36)--Vaginal discharges0.20 (0.00, 0.40)--0.33 (0.00, 0.71)0.37 (0.18, 0.55)----*CoNS* Coagulase negative staphylococci

### Publication bias {#Sec18}

Funnel plots of standard error with Logit event rate (proportion of resistant isolates) supplemented by statistical tests confirmed that there is some evidence of publication bias on studies reporting the prevalence of ciprofloxacin resistance among gram-positive (Begg's test, *p* = 0.086; Egger's test, *p* = 0.026) and gram- negative bacteria (Begg's test, *p* = 0.06; Egger's test, *p* = 0.0003) (Fig. [4](#Fig4){ref-type="fig"}a and b).Fig. 4Funnel plot depicting publication bias **a** Studies describing gram-positive bacteria **b** Studies with gram-negative bacteria

Discussion {#Sec19}
==========

This systematic review and meta-analysis included 37 original studies addressing the prevalence of ciprofloxacin-resistant clinical isolates in Ethiopia within the specified timeframe. Regardless of the source and identity of isolates, the study revealed that one in five clinical isolates were found to be ciprofloxacin resistant in both gram-positive and gram-negative bacteria. *E. faecalis* from gram-positive bacteria and *N. gonorrhoea*, *E. coli* and *K. pneumoniae* from gram-negative bacteria exhibited higher prevalence of resistance as the meta-analysis indicated. The resistance estimate in other enteric pathogens (shigella and salmonella), obtained from stool samples, were found to be relatively less in Ethiopia. Urine and blood samples have been the major source of resistant isolates. In spite of relatively low level of resistance (8.1%) in Ethiopia, the emergence of ciprofloxacin resistance in common salmonella serotypes worldwide is becoming a serious public health concern. Besides, resistance to the first generation quinolones (nalidixic acid) has been associated with reduced efficacy of 6-fluorinated-quinolones such as ciprofloxacin \[[@CR56], [@CR57]\].

Routine antimicrobial surveillance data indicated the presence of strong relationship between antimicrobial use and resistance at a national level in Europe \[[@CR58]\]. Even if quinolones are less likely to select for resistance compared to other natural antibiotics, highly level of use with some degree of misuse facilitates resistance selection and spread of quinolones resistance (QNR) genes to areas where the prevalence of resistance is found to be low \[[@CR59]--[@CR64]\]. Population mobility is a main factor in the spread of antimicrobial--resistant organisms \[[@CR64]\]. To this end, Vernet et al. reported that 65% of *E. coli* strains isolated from patients who had traveled to India were found resistant to quinolones including ciprofloxacin \[[@CR65]\]. Besides, surveillance data showed that resistance in *E. coli* and *K. pneumonia* has become consistently higher for antimicrobial agents that have been in use for long time in human and veterinary medicine \[[@CR12]\]. In trajectory with our findings, significant increment in resistant level of *K. pneumonia* strain against ciprofloxacin was observed from 1998 to 2010 in United States \[[@CR66]\]. Even if fluoroquinolones such as ciprofloxacin and ofloxacin have been highly effective in treating gonorrhea, the widespread and often inappropriate use leads to the emergence of fluoroquinolone resistant *N. gonorrhoea* \[[@CR4], [@CR67]\]. World Health Organization updated the current treatment profiles of *N. gonorrhea* as there has been an established resistance reports from various regions \[[@CR67], [@CR68]\].

To date, several mechanisms of quinolone resistance have been determined: modification of bacterial targets (DNA gyrase or topoisomerase IV) to which quinolones bind, decreased intracellular (bacterial) concentration due to an over-expression of active efflux pumps and enzymatic inactivation (acetylation) of quinolones, among others. Recently, mobile genetic elements carrying the QNR gene, which confer resistance to quinolones, have also been described \[[@CR1], [@CR69]--[@CR71]\]. Amino acid changes in critical regions of the enzyme-DNA complex (quinolone resistance--determining region \[QRDR\]) reduce quinolone affinity for both targets \[[@CR59]--[@CR61]\]. QRDR mutation was identified in Enterococcus isolates; with serine being changed in gyrA83, gyrA87 and parC80. This result showed that gyrA and parC mutations could be important factors for high-level of resistance to such species against ciprofloxacin \[[@CR70]\]. QNR proteins protect target enzymes from quinolone inhibition. The AAC(6′)-Ib-cr determinant acetylates several fluoroquinolones, such as norfloxacin and ciprofloxacin \[[@CR69]\].

Plasmid-mediated quinolone resistance has been shown to compromise the bactericidal activity of fluoroquinolones when expressed in Enterobacteriaceae \[[@CR72]\]. For example, plasmidic transfer of genes has resulted in spread of resistant strains among *E. coli*, *K. pneumoniae*, and Proteus species \[[@CR73]\]. Jacoby et al. described the presence of QNR gene up on analyzing a long series of gram-negative microorganisms (mainly *K. pneumonia* and *E. coli*) from different geographical origins (19 countries) around the world) \[[@CR62]\]. The development of fluoroquinolone resistance in staphylococci, *P. aeruginosa*, and other pathogens can also occur through alterations in DNA topoisomerase \[[@CR74]\]. Besides, an endogenous system which actively transports quinolones out of the bacteria was described initially in *E. coli* and later in other gram-negative and gram-positive bacteria such as *S. aureus* \[[@CR75], [@CR76]\]. The QepA and OqxAB efflux pumps extrude fluoroquinolones from the bacterial cell \[[@CR69]\]. Generally, the above-mentioned mechanisms of resistance have been established upon routine exposure of quinolones for treatment of many bacterial infections. AMR has resulted in increased morbidity, mortality, as well as direct and indirect healthcare costs in developing countries \[[@CR14]\]. A notable example is an epidemic of infection associated with ciprofloxacin resistant *S. typhi* observed in Tajikistan \[[@CR77]\].

Conclusion {#Sec20}
==========

The study revealed that one in five gram-positive or gram-negative bacterial isolates developed resistance against ciprofloxacin in Ethiopia. Among gram-positive bacteria, high level of resistance was observed in Enterococci and CoNS whereas and relatively low degree of resistance was observed among GBS isolates. Within gram-negative bacteria, nearly half of isolates of *N. gonorrhoeae* was found ciprofloxacin resistant. From enterobacteriaceae isolates, *K. pneumonia* and *E. coli* showed relatively higher degree of ciprofloxacin resistance while shigella and salmonella had low level of resistance. Urine and Blood samples were the major sources of ciprofloxacin resistant isolates. Considering resistance estimates in to account, antimicrobial stewardship programs should be established in Ethiopian healthcare settings thereby preserves antimicrobials and contains AMR.
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Additional file 1:**Table S1.** Completed PRISMA checklist. The checklist highlights the important components addressed while conducting systematic review and meta-analysis from observational studies. (DOC 65 kb) Additional file 2:**Table S2.** Data abstraction format. The table presented the ways of data collection (study characteristics and outcome measures) in Microsoft excel format. It also contained a raw data for outcome analyses. (XLSX 27 kb)

AMR

:   Antimicrobial resistance

CoNS

:   Coagulase negative Staphylococci

GBS

:   Group B Streptococci

MeSH

:   Medical subject headings

PRISMA

:   Preferred Reporting Items for Systematic Review and Meta-analysis

QNR

:   Quinolone resistance

QRDR

:   Quinolone resistance determining region

WHO

:   World Health Organization
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